Cardurion Pharmaceuticals, Inc.
Clinical trials sponsored by Cardurion Pharmaceuticals, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to tame rare, Exercise-Triggered heart condition Results expected Apr 2027 (estimated)
-
New heart failure pill shows promise in Mid-Stage trial
Disease control CompletedThis Phase 2 trial tested the drug tovinontrine (CRD-750) against a placebo in 557 adults with chronic heart failure and reduced pumping ability. The goal was to see if the drug safely lowers a key heart stress marker called NT-proBNP over 12 weeks. The study is complete, and res…
Phase 2 • Sponsor: Cardurion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC
-
New heart failure drug shows promise in early trial
Disease control CompletedThis Phase 2 study tested the safety and effectiveness of tovinontrine, an experimental drug, compared to a placebo in 303 adults with chronic heart failure with preserved ejection fraction. The main goal was to see if tovinontrine could lower a key biomarker (NT-proBNP) in the b…
Phase 2 • Sponsor: Cardurion Pharmaceuticals, Inc. • Aim: Disease control
Last updated Sep 03, 2026 00:00 UTC